While the importance of iron for tumor development is widely appreciated, the exact sources of tumor-supporting iron largely remain elusive. The possibility that iron might be provided by stromal cells in the tumor microenvironment was not taken into account so far. In the present study, we show that tumor-associated macrophages (TAM) acquire an iron-release phenotype upon their interaction with tumor cells, thereby increasing the availability of iron in the tumor microenvironment. Mechanistically, TAM expressed elevated levels of the high-affinity iron-binding protein lipocalin-2 (LCN-2), which appeared to be critical for the export of iron from TAM, and in turn enhanced tumor cell proliferation. Moreover, in PyMT-mouse tumors as well as in primary human breast tumors LCN-2 was predominantly expressed in the tumor stroma as compared to tumor cells. LCN-2 expression in the stroma further correlated with enhanced tumor proliferation in vivo. Our data suggest a dominant role of TAM in the tumor iron-management and identify LCN-2 as a critical iron transporter in this context. Targeting the LCN-2 iron export mechanism selectively in stromal cells might open for future iron-targeted tumor therapeutic approaches.
Introduction
MF exhibit a remarkable heterogeneity and functional plasticity described by two extremes, i.e. the classically vs. alternatively activated phenotype, determined by the local environment. 1 Tumor secreted factors, such as IL-10 or TGF-b as well as tumor hypoxia polarize infiltrating monocytes to an antiinflammatory, alternative MF phenotype. 2 As recently suggested, classical MF sequester iron, which is part of the host defense against pathogens in order to restrict iron availability for bacterial growth. 3 In contrast, alternatively activated MF show an increased phagocytic activity, efficiently recycle iron, and release it to their microenvironment in order to promote cell proliferation, tissue repair, and regeneration. 4, 5 Along these lines, breast cancer cells show an increased uptake and intracellular storage of iron in order to support their enhanced metabolism, 6 thereby developing a more aggressive phenotype. 7 Molecularly, this is reflected by an increased expression of ironregulated genes like the transferrin receptor (TfR) 8 for iron uptake, ferritin heavy (FTH) and ferritin light (FTL) 9 for iron storage, and the iron-regulatory protein 2 (IRP2). 10 Expression of these genes correlated with a bad prognosis, poor outcome as well as increased tumor grade. 7 In addition, reduced expression of the only characterized iron exporter ferroportin (FPN) in tumor cells and an increase of its natural ligand hepcidin (HAMP), provoking FPN degradation, significantly enhanced metastasis and increased proliferation. 11 However, the sources of iron within the tumor microenvironment to meet the increased iron demand of tumor cells still remain elusive. We previously showed that TAM, following the interaction with apoptotic tumor cells, produced and secreted LCN-2, 12 a well-established high affinity iron carrier protein in the bacteriostatic context. 13, 14 Mechanistically, the production of LCN-2 was connected to apoptotic cell released sphingosine-1-phophate (S1P) triggered STAT3 activation. 15 MF-derived LCN-2 further promoted tumor progression and breast cancer metastasis, 12, 16 while depletion of LCN-2 inhibited breast tumorigenesis, angiogenesis, lymphangiogenesis, 15, 17, 18 and metastasis 16, 19, 20 in experimental mammary tumor models. These observations were in line with the previous finding that LCN-2 expression is associated with reduced disease-free survival. 21 Based on the apparent pro-tumor function of MFreleased LCN-2 and the established high iron-binding affinity of LCN-2, we aimed to determine if TAM-derived LCN-2 might serve as a novel, so far unappreciated iron transporter during tumor progression.
In the present study, we provide evidence that MF acquire an iron-release phenotype in the tumor context, thus serving as an important source of iron to meet the elevated iron demand of tumor cells and consequently supporting tumor cell proliferation. We further identify LCN-2 as critical determinant of the macrophage iron-release phenotype, which further emerged as an additional iron transporter, alternatively to FPN.
Results
Primary human MF acquire an alternatively activated, iron-release phenotype after co-culture with breast cancer cells Initially, we aimed to determine how tumor cells affect the phenotype and iron-handling properties of MF. To this end, we co-cultured primary human MF with human MCF-7 breast cancer cells (Fig. 1A) . To assess if the MF/tumor cell interplay affects the iron-handling properties of MF upon co-culture for 48 h, we analyzed a panel of iron-regulated genes. After 48 h of co-culture, mRNA expression of the iron exporter FPN and the cellular iron sensor IRP2 was strongly induced, while HAMP, CP, and FTL, representing iron sequestering markers, were significantly reduced in MF (Fig. 1B) , suggesting an iron-release phenotype of MF. Co-culturing primary MF with other breast tumor cell lines, i.e. MDA-MB-231 or T47D cells, confirmed the iron-release pattern (Fig S1A) . Changes at mRNA expression upon co-culture were in a similar range as previously observed after typical alternative-polarizing cytokines such as IL-10 5 and IL-4/Il-13 4 . In line with changes at the mRNA level, FPN protein expression was significantly elevated, while expression of the iron storage protein FTL was reduced in MF upon co-culture with MCF-7 (Fig. 1C, Fig S1B) or other breast tumor cells (Fig S1C,D) . To verify the functionality of the ironrelease phenotype, we determined the iron content in the supernatants of MF by atomic absorption spectrometry (AAS). Supernatants of MF co-cultured with MCF-7 cells contained significantly elevated levels of iron compared to those of control MF (Fig. 1D) . As tumor cells are known to require high amounts of iron to maintain their enhanced metabolic demand, we next aimed to test how changes in the iron amount of MF supernatants might affect tumor cell proliferation. In fact, the supernatants of MF co-cultured with tumor cells enhanced proliferation of MCF-7 cells determined as real-time measurements using the xCELLigence system (Fig. 1E) and by measuring the proliferation marker PCNA at mRNA level ( Fig S1E) . Stimulation of tumor cells with supernatants of na€ ıve macrophages did not significantly enhance tumor cell proliferation. Adding the well described iron-chelator 2'2 DPD to the iron-release MF reversed the effect. Upon co-culture for 48 h, also the surface expression of the alternative MF activation markers MHCII, CD206, and CD163 was markedly elevated in MF compared to na€ ıve control MF (Fig S1F) . In contrast, classical-activation markers CD80, CD86, and CD14 appeared unaltered. Along these lines, mRNA expression of the alternative MF marker IL-10 was enhanced in the co-culture, whereas mRNA expression of the classical MF markers CCL-18, TNF-a, and IL-1b was reduced (Fig S1G) . Taken together, we found that MF acquire an alternative iron-release phenotype upon interaction with tumor cells, which in turn supports tumor growth.
TAM show an iron-release phenotype
Based on our in vitro findings, we next tested if these observations hold true for TAM in vivo. Therefore, we compared the expression of Fpn, Hamp, and Ftl in F4/80 C cells isolated from spontaneously developed mammary tumors of wildtype PyMT mice, i.e. TAM, with the expression in bone marrow-derived MF (BMDM) isolated from the same mouse ( Fig. 2A) . While Fpn mRNA was expressed at similar levels in TAM and BMDM, both Hamp and Ftl mRNA expression was significantly reduced (Fig. 2B) . In line, FPN protein expression remained unaltered, whereas FTL protein was massively reduced (Fig. 2C ) in TAM as compared to BMDM. Despite the unaltered expression of the iron exporter FPN, the intracellular iron amount was markedly lower in TAM compared to control MF (Fig. 2D) , suggesting enhanced iron release. Thus, similar to the in vitro observation, TAM also adopt an iron-release phenotype in vivo. To investigate the different iron-handling ability of MF subpopulations (Fig S2A) , i.e. infiltrating and resident MF, we analyzed the protein expression of FPN and FTL by flow cytometry. In contrast to infiltrating MF, resident MF significantly upregulate FPN expression (Fig. 2E ), but show no difference in FTL expression (Fig. 2F) , indicating the iron release phenotype of this subpopulation. As a functional read-out, we quantified the iron amount in cellular lysates of sorted MF subpopulations. In line with previous FACS results, we observed reduced iron amounts in resident MF (Fig. 2G) . Furthermore, we performed Multi-EpitopeLigand Cartography stainings (MELC) to detect the localization of MF subpopulations within the tumor. Interestingly, we observed that resident MF preferentially appear close to CD31C vessels (Fig S2B) .
FPN knockdown in primary human MF does not alter the iron-release phenotype
As the well-established iron exporter FPN was unaltered in TAM in vivo, yet they still released elevated levels of iron similar to MF in the in vitro co-culture setting, we next determined the role of FPN in the iron-release phenotype of MF in the tumor context. Therefore, we depleted FPN in primary MF using siRNAs (Fig S3A) , prior to co-culturing them with MCF-7 cells. Importantly, the FPN-knockdown efficiently prevented co-culture-induced FPN expression both at mRNA (Fig. 3A , Fig S3B) and protein level (Fig. 3B) . In contrast, the expression of the iron-sequestering markers HAMP and FTL were still reduced in FPN-depleted MF after their co-culture with MCF-7 cells. Similarly, BMDM isolated from wildtype mice reproduced the iron-release phenotype upon co-culture with syngenic E0771 murine breast tumor cells independent of the presence or absence of FPN ( Fig S3C) and were still able to release iron into the supernatant, measured by AAS (Fig S3D) . Despite the fact that FPN is considered as the primary iron exporter, the elevated iron amounts in the supernatants of MF upon co-culture with MCF-7 cells were not reduced, when FPN was depleted in the MF (Fig. 3C ). As the iron availability is critical for tumor progression, we next tested how the tumor cell proliferation-stimulating effect of supernatants of co-cultured MF is affect by attenuating FPN expression. In line with the unaltered iron-release characteristics, supernatants of cocultured wildtype (sictrl) and FPN-depleted (siFPN) MF similarly induced proliferation of MCF-7 cells (Fig. 3D, Fig S3E) , further supporting an alternative iron-release mode.
LCN-2 serves as an alternative iron transporter
We previously found that LCN-2 is secreted from MF upon stimulation with tumor cell supernatants. 12, 15, 16 Taking the high iron-binding affinity of LCN-2 into account, we questioned whether LCN-2 might serve as the alternative iron transporting protein under these conditions. Indeed, LCN-2 was significantly up-regulated in MF after co-culture with various breast cancer cell lines both at mRNA (Fig. 4A ) and protein level (Fig. 4B ). Of note, LCN-2 protein expression in MF after co-culture with tumor cells remained increased, even in FPN knockdown MF (Fig. 4C, Fig S4A) . Similarly, depletion of Fpn in BMDM isolated from wildtype mice reproduced these results upon co-culture with syngenic E0771 murine breast tumor cells (Fig S4B) . To assess, if elevated LCN-2 levels affect the iron- release from MF, we determined the iron-loading status of LCN-2. Therefore, we immunoprecipitated LCN-2 both from supernatants as well as from cell lysates of na€ ıve or co-cultured MF and determined the relative iron content by AAS. LCN-2-bound iron was markedly elevated in the supernatants after co-culture, while it decreased in the cellular fraction (Fig. 4D) , suggesting that iron-loaded LCN-2 is efficiently released from MF. To assess if MF-supplied iron-loaded LCN-2 might contribute to FPN-independent iron-mediated increase in tumor cell proliferation, we neutralized LCN-2 in the supernatant of FPN-depleted MF using a specific antibody. In fact, depleting LCN-2 in the supernatants of FPN knockdown MF significantly reduced tumor cell proliferation (Fig. 4E, Fig S4C) .
To provide further evidence for the importance of LCN-2 in TAM, we knocked down LCN-2 in primary human MF (Fig S5A,B) , and found that LCN-2-depleted MF did not show an iron-release gene expression profile after tumor cell co-culture, i.e. neither was FPN increased nor were HAMP or FTL reduced (Fig. 5A, Fig S5C) . In line, LCN-2 knockdown MF did not show elevated FPN or reduced FTL protein expression upon co-culture with tumor cells in contrast to sictrl-transfected MF (Fig. 5B) . Importantly, the analysis of the iron content of the supernatants further revealed that depletion of LCN-2 in MF completely abolished the co-cultureinduced iron-release (Fig. 5C) . Consequently, supernatants of LCN-2-depleted MF after co-culture failed to enhance proliferation of tumor cells (Fig. 5D, Fig S5D) . To further proof the importance of LCN-2 as an iron-supply system for tumor cells in this context, we supplemented supernatants of LCN-2-knockdown MF with recombinant ironloaded LCN-2 ( Fig S5E) and observed that the addition of recombinant iron-loaded LCN-2 to the supernatant of siLCN-2 MF rescued cancer cell proliferation (Fig. 5D,  Fig S5D) .
Thus, LCN-2 emerges as an alternative iron transporter in the interplay between tumor cells and MF, where it critically contributes to the iron transport from MF to the tumor cell, thereby supporting tumor progression. The iron-release phenotype of TAM depends on LCN-2 Since LCN-2 appeared to be involved in the TAM-induced protumorigenic effects, we next explored the role of LCN-2 in the MF iron-release phenotype by using LCN-2 ¡/¡ macrophages. To this end, we co-cultured BMDM isolated from wildtype or LCN-2 ¡/¡ mice with syngenic E0771 mouse breast cancer cells. The iron-regulated gene expression profile obtained in wildtype BMDM after co-culture with E0771 cells pointed to an ironrelease profile (Fig. 6A, left panel) , closely resembling the observation in primary human MF (Fig. 1D) (Fig. 6A, right panel) . Similarly, the enhanced FPN protein expression upon co-culture in wildtype BMDM was absent in LCN-2 ¡/¡ -BMDM and the FTL protein reduction observed in wildtype BMDM upon co-culture was even reversed in LCN-2-deficient BMDM (Fig. 6B) . To test, if these iron-marker profiles were functionally effective, we determined the iron release of BMDM upon co-culture. In analogy to the human system, supernatants of BMDM contained higher iron amounts after tumor cell co-culture than na€ ıve BMDM (Fig. 6C, open bars) . In contrast, LCN-2 ¡/ ¡ -BMDM released less iron upon co-culture compared to na€ ıve BMDM (Fig. 6C, solid bars) . Thus, LCN-2-knockout MF did not adopt an iron-release phenotype upon contact with tumor cells in vitro. Corroborating the role of LCN-2 as high-affinity iron-binding protein delivering iron from macrophages to the tumor microenvironment. Surprisingly, the important ironexporter FPN appeared to be dispensable in the macrophagetumor interplay, whereas loss of LCN-2 not only attenuated iron-release from macrophages, but also the associated tumor cell proliferation.
LCN-2 is predominantly expressed in TAM and contributes to enhanced tumor growth
To assess, the in vivo relevance of our observations, we determined tumor cell proliferation in wildtype and LCN-2-deficient PyMT mice. Corroborating in vitro findings, the tumor burden (Fig. 6D ) and number of proliferating, i.e. Ki67-positive cells (Fig. 6E) , was strongly reduced in tumors of LCN-2 knockout mice as compared to wildtype mice. To rule out that changes in tumor cell proliferation were due to an altered composition of the immune infiltrate rather than differences in MF function, we analyzed various myeloid cell types within PyMT tumors by flow cytometry. The infiltration of monocytes, resident MF, and TAM was unaltered in LCN-2-deficient as compared to wildtype mice (Fig. 6F) . To test if LCN-2 is similarly important for the iron-release phenotype of TAM in vivo, we sorted TAM from tumor-bearing wildtype and LCN-2 ¡/¡ PyMT mice. LCN-2-deficient TAM expressed similar levels of Fpn mRNA, while the mRNA expression of iron sequestration markers Hamp and Ftl was significantly elevated compared to TAM isolated from wildtype tumors (Fig. 7A) . Accordingly, the intracellular iron amount was significantly increased in LCN-2 ¡/¡ -TAM (Fig. 7B , solid bars) compared to wildtype TAM (Fig. 7B, open bars) , suggesting that more iron was retained in LCN-2-deficient TAM.
As LCN-2 was depleted in all cells in this animal model, we next analyzed LCN-2 expression in sorted tumor cells and TAM from tumors of wildtype PyMT mice to determine the prime source of LCN-2 in this context. In line with previous observations, 15, 16, 22 TAM expressed higher levels of Lcn-2 mRNA than the tumor cells (Fig. 7C) . To gain further evidence for the differential distribution of LCN-2 within the tumor context and to further translate our findings to the human situation, we determined LCN-2 protein expression using immunohistochemistry in human breast tumor samples employing the Vectra system. In fact, LCN-2 protein was predominantly expressed in the stromal compartment of the tumors (Fig. 7D,E) , supporting the concept that stroma-derived LCN-2 might serve as an iron source for tumors in vivo. We next aimed to determine if LCN-2 expression holds predictive power for breast cancer patients. To this end, we performed meta analyses of available data sets 23, 24 LCN-2 expression positively correlated both with the rate of recurrence in breast cancer patients as well as with the histological grade (Fig. 7F) .
Considering the skewed distribution of LCN-2 expression towards TAM in the tumor, these findings underline the potential of LCN-2 expression in the stroma as a novel prognostic marker for breast cancer patients.
In summary, we propose that TAM support tumor growth by supplying the latter with iron via an LCN-2-mediated, FPNindependent transport (Fig. 7G) . LCN-2 in the tumor stroma therefore might be a promising target for novel therapeutic approaches aiming at restricting the iron-availability of tumors.
Discussion
In the present study, we present evidence for an iron-release phenotype of TAM contributing to tumor cell proliferation. As LCN-2 was primarily found in the stroma of primary human breast cancer samples as well, and LCN-2-deficiency limits tumor cell proliferation in vivo, LCN-2 in TAM might be a promising novel tumor therapeutic target.
While the importance of MF for tumor development and progression is widely appreciated, and the elevated irondemand of tumors is also well established, a potential connection between TAM and the tumor iron supply remains largely elusive. Our observation that TAM release iron into the tumor microenvironment via an LCN-2 mediated mechanism therefore provides first insights into the role of TAM in the tumor iron management. Previously, LCN-2 expression in tumors was correlated with poor prognosis and suggested to support tumor development and metastatic spread, 25, 26 but the effect of MFsecreted LCN-2 and its iron-load during tumor progression was not investigated so far. First studies suggested that LCN-2 positive staining increases in advanced breast cancer stages. 21, 26 Along these lines, we previously showed that MF-derived LCN-2 supports metastasis. 16 Our present data indicate that TAM are an important source of iron in the tumor microenvironment. Moreover, we found that TAM release iron bound to the iron transporting protein LCN-2 into the tumor microenvironment. The observation that MF acquire an iron-release phenotype corroborates previous reports suggesting an ironrelease phenotype in alternatively activated MF. 4, 5 Interestingly, depletion of the established iron exporter FPN in TAM neither affected the iron-release from TAM nor did it attenuate enhanced proliferation of MCF-7 tumor cells upon stimulation with MF supernatants. In contrast, LCN-2 knockdown abolished iron release and proliferation. Thus, LCN-2 emerges as a major iron transporter in this context. In line with our findings, it was previously suggested that iron sequestration in LCN-2 ¡/¡ MF ensures host defense against salmonella typhimurium infection by controlling MF iron homeostasis. 27 Of note, depletion of LCN-2 also markedly reduced FPN expression, suggesting that LCN-2 and FPN might act in concert to export iron from TAM. We speculate that the depletion of LCN-2 alters iron-dependent gene expression and/or the labile iron pool, which might result in a negative regulation of FPN and/ or its degradation. However, further studies are needed to determine the exact mechanistic links and/or interplay between these iron export pathways in TAM.
Tumors demand an excess of iron, both during early steps of tumor development, e.g. for enhanced survival 28 and proliferation of transformed cells, 29 but also during metastasis to facilitate remodeling of the extracellular matrix, and to increase motility and invasion of cancer cells. 30 Our findings that MF actively release iron in the tumor context suggest a central role of MF in regulating tumor iron homeostasis. Along the same lines, high expression of a variety of iron-regulated genes such as HAMP and FTL correlated with poor prognosis, a higher tumor grade, and increased chemoresistance. 31 Furthermore, clinical studies inversely correlated the expression of FPN in human breast tumors with patient survival and disease outcome. 11 Interestingly, in our setting FPN depletion did not affect the iron-release from MF and consequently did not alter the pro-tumorigenic properties of MF supernatants. Similarly, it was recently suggested that MF release ferritin, 32 thereby supporting tumor development. Moreover, enhanced ferritin expression was found in the tumor stroma. 9 Since we did not observe elevated ferritin levels in TAM and taking into account that LCN-2 in tumor patients correlated with bad prognosis, we suggest that the high-affinity iron-binding protein LCN-2 33 serves as an alternative iron transporter, supplying tumor cells with iron. However, in the present study we observed reduced ferritin levels only at mRNA level, whereas secretion was not checked. Furthermore, the iron-handling properties of different MF subpopulations, i.e. infiltrating vs. resident MF indicated that ferritin expression was not elevated in the PyMT breast cancer model. However, it might well be that ferritin secretion accounts for enhanced iron release in a particular subpopulation, i.e. CD163C MF as described previously for human tumors. 9 The iron-loading status of LCN-2 has previously been shown to be decisive for its biological activity, i.e., iron-loaded LCN-2 favors cell survival and proliferation by enhancing the intracellular iron concentration and the induction of protective Bcl-2. However, internalization of iron-free LCN-2 promotes cell death by LCN-2-dependent intracellular iron deprivation and the concomitant increase of the pro-apoptotic Bim. 34 In summary, we propose that TAM-derived LCN-2 serves as a crucial iron transporter in breast cancer, thereby providing an additional iron source for tumor cells. So far, most iron-targeting therapeutic approaches focused on modulating the aberrant iron homeostasis directly in tumor cells, largely ignoring the impact of infiltrating stromal cells. Our study underscores the significance of stroma-derived iron for tumor progression. Taking the previously proposed negative prognostic properties of LCN-2 for breast cancer patients and the herein characterized iron-supply function of LCN-2 in the tumor context into account, targeting LCN-2 in TAM might open a novel therapeutic approach to limit iron availability, specifically for tumors, without affecting classical iron transport routes.
Materials and methods

Materials
If not indicated otherwise, all chemicals were purchased from Sigma Aldrich.
Primary MF generation
Human monocytes were isolated from commercially available buffy coats (DRK-Blutspendedienst Baden-W€ urttembergHessen, Frankfurt, Germany) using Ficoll-Hypaque gradients (PAA Laboratories). Monocytes were differentiated into primary human MF with RPMI 1640 containing 5% AB-positive human serum (DRK-Blutspendedienst) for 7 days and achieved approximately 80% confluence. 24 h prior to stimulation, cells were serum-starved. Conditioned media of polarized MF were collected, centrifuged at 1000 x g for 5 min at 4 C, and aliquots were stored at -80 C until further use. Supernatant of unstimulated MF served as control.
Generation of murine BMDM
Murine BMDM were generated by isolating the bone marrow of wildtype and LCN-2 ¡/¡ mice. Cells were differentiated directly in 6-well plates (6 £ 10 6 cells/well) in the presence of 10 ng/ml MF colony-stimulating factor (GM-CSF) (Peprotech) for up to 7 days. At day 3, fresh GM-CSF was added.
Tumor cell culture
The human breast cancer cell lines MCF-7, MDA-MB-231, and T47D as well as the murine breast cancer cell line E0771 were cultured in Dulbecco's modified Eagle medium (DMEM) with high glucose (Life Technologies), supplemented with 100 U/ml penicillin (PAA), 100 mg/ml streptomycin (PAA), and 10% fetal calf serum (FCS; PAA). Tumor cells were cultivated in a humidified atmosphere with 5% CO 2 at 37 C and passaged 3 times per week. 24 h prior to stimulation, cells were serum starved. Each cell line was routinely tested for mycoplasma. 22 DPD was used in a 100 mM concentration.
Co-culture of primary MF with breast cancer cells
MF were isolated and differentiated as described above. For the co-culture, tumor cells were harvested by trypsin, washed once with PBS and suspended in MF medium. MF and cancer cells were cultured in a 1:1 ratio for 48 h in MF medium in a humidified atmosphere of 5% CO 2 at 37 C. At the end of the co-culture, conditioned media was harvested and stored for further use at -80 C. The remaining tumor cells were removed by applying accutase and MF were processed for further analysis.
Small interfering RNA (siRNA) transfections
GenMute
Ò transfection reagent (SignaGen) was used according to the manufacturer's instructions. 50 nM LCN-2 siRNA or 50 nM FPN siRNA (Qiagen) was transfected into primary MF. A non-targeting, scrambled siRNA (sictrl) was used as control.
Proliferation assay
Proliferation of human MCF-7 breast cancer cells was measured using the RTCA DP xCELLigence instrument (OLS) as described previously. 15 Data are presented as the slope per hour (slope 1/h) of the normalized cell index as a measure for the time-dependent changes in impedance. To determine the proliferation marker proliferating-cellnuclear-antigen (PCNA), MCF-7 cells were treated for 24 h with MF-supernatant (MF-SN) and gene expression was measured by qPCR.
RNA extraction and quantitative real-time PCR (qPCR)
RNA was extracted using peqGold RNAPure reagent (Peqlab). Total RNA (1 mg) was transcribed using the Maxima firststrand cDNA synthesis kit (Fermentas). qPCR was performed using the MyIQ real-time PCR system (BioRad) and Absolute Blue qPCR SYBR green fluorescein mix (Thermo Fisher). qPCR results were quantified using the Bio-Rad CFX Manager (version 3.1) software program from Bio-Rad, with 18 S mRNA expression as an internal housekeeping gene control for human samples and Tbp for murine samples. All primers were bought from Biomers, except the human LCN-2 primer, which was bought from Qiagen. Changes were determined relative to the respective expression in na€ ıve control MF (ctrl).
Atomic absorption spectrometry
The iron content bound to proteins in the supernatant and the whole iron amount in the lysates was determined by graphite furnace atomic-absorption-spectrometry. Therefore, supernatants were concentrated using Amicon Ò Ultra-4 centrifugal filter devices (Merck Millipore). Samples were measured as triplicate with a PinAAcle TM 900 T atomic-absorption-spectrometer (PerkinElmer). A wavelength of 248.33 nm and a slit width of 0.2 mm were used as spectrometer parameters. A hollow cathode iron lamp (30 mA maximum operating current) was run at 100% maximum current. The calibration solutions (10 mg/l to 90 mg/l) were prepared by adequate dilution of iron standard for AAS (Sigma-Aldrich) stock solution. A pyrolysis temperature of 1400 C and an atomization temperature of 2100 C were used. The iron amount was quantified relative to the protein content and normalized to na€ ıve control MF (ctrl), if not other indicated.
Generation of recombinant LCN-2
Recombinant human LCN-2 was produced by transformation of E.coli with a pGEX-4 T-3-NGAL plasmid as already described. 16 In order to test efficient LCN-2-catechol-iron complex formation, UV-visible spectroscopy (UV-vis) was used. Therefore, 10 mM LCN-2 were incubated with 10 mM catechol (Sigma) and 10 mM iron (Sigma).
ELISA
Detection of secreted LCN-2 was performed as previously described. 16 LCN-2 content was calculated by the amount per mg of total protein (ng/mg protein). The anti-LCN-2 antibody was bought from R&D (MAB1857, MAB1757) and the secondary anti-rat IgG antibody was purchased from DAKO. Both Streptavidin-HRP and color reagent were from R&D.
LCN-2 immunoprecipitation
For immunoprecipitation (IP), primary human MF were cocultured for 48 h with MCF-7 tumor cells. After removing the remaining tumor cells, MF were lysed on ice for 30 min in IP buffer (50 mM Tris-HCl pH 7.4, 300 mM NaCl, 5 mM EDTA, 1% NP-40, 1 mM PMSF, 1x protease and phosphatase inhibitor mix, 1 mM Na 3 VO 4 ). Dynabeads (Thermo Fisher) were added and 1 mg protein was incubated overnight at 4 C in the presence of a specific antibody against LCN-2 (R&D, MAB1757). Beads were precipitated using the DynaMag-2 magnet (Thermo Fisher) and washed three times with IP buffer. Protein was eluted by addition of 2x loading buffer and incubated at 95 C for 5 min.
Animal studies
MMTV-PyMT breast cancer model Wildtype and LCN-2
¡/¡ mice with or without crossing into a Polyoma-middle-T (PyMT) background were used. For genotyping, tail-tips were lysed with KAPA Genotyping lysis buffer (Peqlab) and the resulting DNA solutions were analyzed by PCR amplification using KAPA Hotstart Genotyping reaction mix (Peqlab). Tumor growth was monitored using sliding calipers until mice developed a maximal tumor diameter of 1.5 cm. After sacrificing mice, both the tumor and BMDM were isolated.
Flow cytometric analyses
For analysis of in vitro samples, MF were detached using accutase (PAA). Tumors from PyMT mice were dissociated using the Tumor Dissociation Kit (Miltenyi) and the GentleMACS system (Miltenyi). Samples were acquired with a LSRII/Fortessa flow cytometer (BD) expressed as mean fluorescence intensity (MFI). All antibodies and secondary reagents were titrated to determine optimal concentrations. CompBeads (BD) were used for single color compensation to create multi-color compensation matrices. For gating, fluorescence minus one (FMO) controls were used. The instrument calibration was controlled daily using Cytometer Setup and Tracking beads (BD). 
/CD326
C living tumor cells and F4/80 C / CD326 ¡ TAM were sorted using a FACS Aria (BD). Cells were harvested for AAS or directly used for RNA isolation applying the RNeasy microKit (Qiagen). For conversion of mRNA to cDNA, the Sensiscript RT kit (Qiagen) was used.
Multiplex immunohistochemistry
Tumor sections from PyMT mice were subjected to antigen retrieval and stained with an antibody against Ki-67 (Abcam, ab15580) according to manufacturers instructions using the Opal TM 4-Color Fluorescent IHC Kit (Perkin Elmer). DAPI was used for nuclear visualization. As secondary antibodies, linked to horseradish peroxidase (HRP) an anti-rabbit (GE Healthcare, NA934-1 ML) antibody was used. Images were acquired using the Vectra automated imaging system and analysis was performed using Inform software.
MELC
MELC robot technology involved validated distinct hardware and software components as described earlier. 35 Murine primary tumors were immediately frozen and used for frozen sections (4 mM). Before staining, sections were fixed wit 4% paraformaldehyde/PBS for 10 min. Cells were permeabilized with 0.1% Triton X-100/PBS for 10 min and incubated with 3% BSA/PBS for 60 min. The coverslip was placed onto a customized sample holder (2-mm thickness, inner diameter of 16 mm) and fixed with an adapted silicon ring (outer diameter 2 cm, inner diameter 1 cm) that also served as antibody incubation chamber. The sample was positioned onto an inverted fluorescence microscope (Leica DM IRE2; 63 oil objective lens). By a robotic pipetting process, the specimen was incubated with fluorophore-labeled antibodies and wash solutions. Phase contrast and fluorescence signals were recorded, followed by a bleaching step (488 nm for FITC and 546 nm for phycoerythrin). A postbleaching image was taken and subtracted from the image taken from the following epitope. Signals were validated using conventional immunehistochemistry. Recording and processing of all image data and the coordination of all system components were fully automatically controlled by software developed by MelTec GmbH (Magdeburg, Germany).
Primary human tumor samples
4-mm sections of the recipient block were mounted onto slides, subjected to antigen retrieval, and stained with an antibody combination consisting of LCN-2 (R&D, MAB1757) and pancytokeratin (panCTK) (Abcam, ab7753) according to manufacturers instructions using the Opal TM 4-Color Fluorescent IHC Kit (Perkin-Elmer). DAPI was used for nuclear visualization. Horseradish peroxidase (HRP) coupled anti-mouse (GE Healthcare, NA931.1 ML) or anti-rat (GE Healthcare, NA935-1 ML) secondary antibodies was used for detection. Images were acquired using the Vectra automated imaging system and analysis was performed using ImageJ. Specifically, the background was substracted using the rolling circle function and the channels were demixed during this process (the rolling circle radius was set to at least the size of the largest object that is not part of the background which was determined a priori). Thresholds were set semi-automatically for the pre-processed images. Under-or overexposed images were discarded from further analysis. For quantitative analysis, the images were then converted to binary images and the signal distribution was determined for each color individually.
Study approval
Investigations were conducted in accordance with the ethical standards according to the Declaration of Helsinki and to the national and international guidelines and have been approved by the authors' institutional review board. All procedures involving mice followed the guidelines of the Hessian animal care and use committee. Primary human tumor sections were prepared from representative areas of 198 invasive, paraffinembedded tumors from premenopausal patients with lymphnode negative breast cancer, with the approval of the research ethics committee of Lund University (Regionala etikpr€ ovningsn€ amnden, LU 240-01 and Drn 2016/789).
Meta analyses of LCN-2 expression with breast cancer grade and recurrence
Correlation between LCN-2 expression in primary human breast tumors and given data were assessed with gene expression profiles from accessible microarray data sets. To this end, we used the following studies from Ma et al. (GSE1379), 36 and Desmedt et al. (GSE7390) . 24 Statistical analysis were performed with GNU R version 3.3.2. 37 The significance levels were assessed with the Welch two-sample t-test.
Statistical analysis
Statistical analysis was performed using Prism software (GraphPadSoftware Inc.). Values for all measurements were expressed as means § SEM. Each experiment was performed at least three times (independent experiments using three technical replicates). Data were analyzed using One-way ANOVA. Patient samples were statistical analyzed using the Mann-Whitney-U test. P values were considered significant at Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001.
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